U.S. stocks climbed on Tuesday, forced by hopes for a contract between Greece and its international creditors.

At 12:47 pm, the biotech sector’s summary was somewhat like this:

• Anthera Pharmaceuticals Inc (NASDAQ:ANTH), is the top gainer of the Healthcare sector for the current trading session, and added 23.85% to the share.
• Biocept Inc (NASDAQ:BIOC), is among the top loser of the sector, losing -38.92% from the share, and is now trading at $1.13, and recently hits new 52-week low of $1.09.
• Pfizer Inc (NYSE:PFE), recently hits new 52-week high of $34.00, and is now trading at $33.90, and is the most active stock for the session, gaining volume of 22.46M.
• Anthera Pharmaceuticals Inc (NASDAQ:ANTH), is the most volatile stock in the meantime, and it remained 6.12% volatile for the week and 9.28% for the month.
• Seattle Genetics, Inc (NASDAQ:SGEN), will release its earning report, after the market close today.

Following are the details of few declining healthcare stocks for the current trading session:

Biocept, Inc. (NASDAQ:BIOC), declined sharply -39.46% and is now trading at $1.12, soon after, a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, recently declared the pricing of an underwritten public offering of 8,000,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 8,000,000 shares of its ordinary stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable right away and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are predictable to be about $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of ordinary stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is predictable to close on February 13, 2015, subject to customary closing conditions.

Biocept, Inc. (NASDAQ:BIOC), headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment.

Shares of Coherus Biosciences, Inc. (NASDAQ:CHRS) dipped -8.78% and is now at $29.52, following the recent news that a late-stage clinical biologics platform company focused on the global biosimilar market, recently declared that it will take part in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City.

Coherus Biosciences, Inc. (NASDAQ:CHRS), is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our aim is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), dropped -0.53% and is now at $397.59, soon after a leading science-based biopharmaceutical company based in Tarrytown, New York, declared financial results for the fourth quarter and full year 2014 and offered an update on development programs.

• In the fourth quarter of 2014, net sales of EYLEA in the United States raised 29% to $518 million from $402 million in the fourth quarter of 2013. For the full year 2014, net sales of EYLEA in the United States raised 23% to $1.736 billion from $1.409 billion for the full year 2013. Overall distributor inventory levels remained within the Company’s one- to two-week targeted range.

• Bayer HealthCare commercializes EYLEA outside the United States. In the fourth quarter of 2014, net sales of EYLEA outside of the United States(1) were $297 million, contrast to $184 million in the fourth quarter of 2013. In the fourth quarter of 2014, Regeneron recognized $88 million from its share of net profit from EYLEA sales outside the United States (after repayment of $14 million in development expenses), contrast to $44 million in the fourth quarter of 2013 (after repayment of $15 million in development expenses). For the full year 2014, net sales of EYLEA outside of the United States(1) were $1.039 billion, contrast to $472 million in 2013. For the full year 2014, Regeneron recognized $301 million from its share of net profit from EYLEA sales outside the United States (after repayment of $57 million in development expenses), contrast to $102 million in 2013 (after repayment of $58 million in development expenses).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Shares of the Hemispherx Biopharma, Inc. (NYSE:HEB) dipped -3.72%, as Based upon numerous Hemispherx stockholder requests, an advanced specialty pharmaceutical company, has posted the report and findings of the recent efficacy study of Ampligen(R) in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by TheStreet.com’s blogger Adam Feuerstein and invalidates Feuerstein’s negative social media postings about the company’s press release that was issued on February 2, 2015.

Hemispherx Biopharma, Inc. (NYSE:HEB), is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities (“biological modifiers”) for treatment of seriously debilitating disorders especially life-threatening viruses.

Atossa Genetics, Inc. (NASDAQ:ATOS), dwindled -6.25% and is now at $1.43, following the news that the Breast Care Company, has signed an contract with Thermo Fisher Scientific for distribution of Atossa’s FullCYTE Breast Aspirator device in the United States through the Fisher HealthCare channel. Atossa’s FullCYTE Breast Aspirator is used by physicians and nurses to collect nipple aspirate fluid from a patient’s breasts for cytological analysis.

Atossa Genetics, Inc. (NASDAQ:ATOS), is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its partner, The National Reference Laboratory for Breast Health, Inc.